CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION

Since the middle of the previous century the heterogeneity of breast cancer became absolutely evident. This assumption was historically based on differences in clinical behavior and sensitivity to therapy. Treatment approach nowadays is based primarily on clinical and morphological prognostic and predictive markers. Among morphologically derived markers the most important are estrogen and progesterone receptors and HER2. Interestingly that tumors with expression of estrogen receptors and/or progesterone receptors that showed also hyperexpression or amplification of HER2 have very poor outcome and low sensitivity to all therapeutic approaches. Therefore we want to summarize the existing clinical information that is relevant to this topic